MicropatchTM solid dose skin delivery system

This item was submitted to Loughborough University's Institutional Repository by the/an author.


Additional Information:

- This is a conference abstract. The conference website is at: https://www.ukpharmsci.org/

Metadata Record: https://dspace.lboro.ac.uk/2134/18598

Version: Accepted for publication

Publisher: © the authors, Academy of Pharmaceutical Sciences of Great Britain

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Please cite the published version.
MICROPATCH™ SOLID DOSE SKIN DELIVERY SYSTEM

Karmen Cheung¹, Dewan F. Chowdhury² Diganta B Das¹
¹Department of Chemical Engineering, Loughborough University, Loughborough LE11 3TU, UK
²Nemaura Pharma Ltd., Charnwood Building, Holywell Park, Loughborough LE11 3AQ, UK

Abstract - The Micropatch™ solid dose skin delivery device combines the use of a solid stainless steel microneedle and the insertion of a solid drug loaded pellet which is inserted into the skin to the desired depth. Results showed that the solid dose injector is an efficient method to allow complete release of diclofenac sodium after 10 minutes.

INTRODUCTION

The administration technique of the Micropatch™ allows a drug dosage form ranging from several hundred microns to several millimetres to be inserted into the skin in a rapid user-independent manner [1]. The principle of the device is based upon the initial insertion of a super sharp stainless steel needle to breach the tough outer barrier of the skin, followed by a secondary drug carrier which contains the drug dosage form. The device allows the drug formulation to be inserted efficiently into the skin at any specified depth. The Micropatch™ device differs to conventional microneedle technology techniques such as the ‘poke and patch’, ‘coat and poke’ or biodegradable microneedles and can overcome the disadvantages and limitations associated with these techniques [2-5]. This includes the ability of the Micropatch™ to deliver a defined drug loading in to the skin, eliminating the poor reproducibility of dosing associated with large array microneedle patches. The instantaneous administration of the drug minimises the residual time required for the needles to be inside the skin, and therefore can lead to less irritation and therefore reduced user discomfort.

MATERIALS AND METHODS

Diclofenac sodium was used as the model drug to be used in conjunction with the Micropatch™ device has been developed in conjunction with Nemaura Pharma Limited (Loughborough, UK). A diclofenac sodium pellet was inserted into full thickness porcine skin using the Micropatch™ device and a series of images taken (Fig. 1). Dissolution of the pellet was also conducted.

RESULTS AND DISCUSSION

The results (Fig. 1) show that the Micropatch™ was able to successfully insert the pellet to a penetration depth of 2 mm from the base of the Micropatch™. The porcine skin was shown to reseal after 30 minutes (as shown in Fig. 1. Image H). The dissolution study showed that a total drug release of diclofenac sodium occurred after 10 minutes (Fig. 2).

REFERENCES